{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). The PD-linked mutations I2020T and G2019S, located in the activation loop of the kinase domain, have been shown to alter kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as altered kinase activity due to mutations in LRRK2, which is associated with Parkinson's disease (PD). The specific location of I2020T in the activation loop suggests a direct impact on kinase function, relevant to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity... using an in vitro kinase activity assay.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays used (TR-FRET competitive binding assays and radiometric kinase activity assays) are standard in the field for assessing kinase activity and ATP affinity, directly relevant to the disease mechanism of altered kinase function in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Kinase reactions were performed in duplicate at room temperature... All assays were performed using either three or four replicates for each data point represented... Reactions performed at 1 mM ATP included 24 nM wild-type, 8.3 nM G2019S, and 56 nM I2020T.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states the use of wild-type LRRK2 as a normal control and compares it with mutant variants (I2020T and G2019S) as abnormal controls. Additionally, multiple replicates (duplicates, triplicates, or quadruplicates) are mentioned for the experiments.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compound affinities were compared for wild-type LRRK2, I2020T, and G2019S... ATP affinities were compared among the LRRK2 variants with the TR-FRET competitive binding assay.",
          "judgment": "Yes",
          "reasoning": "The paper uses G2019S, a known pathogenic variant for PD, as a control alongside I2020T and wild-type LRRK2 in the assays, satisfying the requirement for variant controls with known pathogenic status.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "ATP Km,app and Vmax values were determined by fits of the Michaelis-Menten equation to the data... IC50 values for sunitinib were determined with a TR-FRET kinase activity assay... Curve fitting and data analysis were performed with GraphPad Prism software.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data (e.g., Km,app, Vmax, IC50 values) and mentions curve fitting, it does not provide specific statistical analyses or p-values to estimate OddsPath for pathogenicity likelihood. Direct calculation or inference of OddsPath is absent.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Compound affinities were compared for wild-type LRRK2, I2020T, and G2019S for six kinase inhibitors... ATP affinities were compared among the LRRK2 variants.",
          "judgment": "Less than 11 controls",
          "reasoning": "The study uses only two variant controls (G2019S as pathogenic and wild-type as benign), totaling less than 11 controls. Therefore, the evidence strength is limited to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 I2020T supports pathogenicity at a supporting level (PS3_supporting) due to demonstrated altered kinase activity and ATP affinity relevant to PD mechanism. However, the lack of sufficient statistical analysis for OddsPath and limited number of variant controls (less than 11) restricts the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in leucine-rich repeat kinase 2 (LRRK2) are a frequent cause of late-onset autosomal dominant Parkinson's disease (PD). The PD-linked mutations I2020T and G2019S, located in the activation loop of the kinase domain, have been shown to alter kinase activity.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as altered kinase activity due to mutations in LRRK2, associated with Parkinson's disease (PD). The specific location of G2019S in the activation loop indicates a direct impact on kinase function relevant to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "We demonstrate by both binding and enzymatic assays that alterations in the kinase activity of the PD-associated mutants I2020T and G2019S are due in part to altered ATP affinity... using an in vitro kinase activity assay.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays used (TR-FRET competitive binding assays and radiometric kinase activity assays) are standard in the field for assessing kinase activity and ATP affinity, directly relevant to the disease mechanism of altered kinase function in PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Kinase reactions were performed in duplicate at room temperature... All assays were performed using either three or four replicates for each data point represented... Reactions performed at 1 mM ATP included 24 nM wild-type, 8.3 nM G2019S, and 56 nM I2020T.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly states the use of wild-type LRRK2 as a normal control and compares it with mutant variants (I2020T and G2019S) as abnormal controls. Additionally, multiple replicates (duplicates, triplicates, or quadruplicates) are mentioned for the experiments.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Compound affinities were compared for wild-type LRRK2, I2020T, and G2019S... ATP affinities were compared among the LRRK2 variants with the TR-FRET competitive binding assay.",
          "judgment": "Yes",
          "reasoning": "The paper uses I2020T, another variant associated with PD, as a control alongside G2019S and wild-type LRRK2 in the assays, satisfying the requirement for variant controls with known pathogenic status.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4a: Statistical Analyses",
          "extracted_paper_info": "ATP Km,app and Vmax values were determined by fits of the Michaelis-Menten equation to the data... IC50 values for sunitinib were determined with a TR-FRET kinase activity assay... Curve fitting and data analysis were performed with GraphPad Prism software.",
          "judgment": "No",
          "reasoning": "While the paper provides quantitative data (e.g., Km,app, Vmax, IC50 values) and mentions curve fitting, it does not provide specific statistical analyses or p-values to estimate OddsPath for pathogenicity likelihood. Direct calculation or inference of OddsPath is absent.",
          "next_step_or_outcome": "Proceed to Step 4b"
        },
        {
          "step_name": "Step 4b: No OddsPath Calculation",
          "extracted_paper_info": "Compound affinities were compared for wild-type LRRK2, I2020T, and G2019S for six kinase inhibitors... ATP affinities were compared among the LRRK2 variants.",
          "judgment": "Less than 11 controls",
          "reasoning": "The study uses only two variant controls (I2020T as pathogenic and wild-type as benign), totaling less than 11 controls. Therefore, the evidence strength is limited to supporting level.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S supports pathogenicity at a supporting level (PS3_supporting) due to demonstrated altered kinase activity and ATP affinity relevant to PD mechanism. However, the lack of sufficient statistical analysis for OddsPath and limited number of variant controls (less than 11) restricts the strength to supporting."
    }
  ]
}